Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
The present invention relates to oxygenated amino and ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.
1. A method of treating or ameliorating an inflammatory, autoimmune and/or allergic disorder, the method comprising the administration of a compound of formula 1 to a subject in need of such a treatment or amelioration, wherein the compound of formula 1 is
or a pharmaceutically acceptable salt thereof,
wherein
R 1 is a C 10-20 hydrocarbon group;
R 2 is a C 1-4 alkyl group, and R 3 is —H, or R 3 is absent;
R 4 is a C 3-6 alkylene group which is substituted with one or more groups independently selected from —OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), —O—C(O)—O(C 1-3 alkyl), —O—C(O)—NH 2 , —O—C(O)—NH(C 1-3 alkyl), —O—C(O)—N(C 1-3 alkyl)(C 1-3 alkyl), —O(CH 2 ) 2 OH, or —O(CH 2 ) 3 OH;
R 5 is —SO 3 − , —SO 3 H, —PO 3 H − , —PO 3 2− , —PO 3 H 2 , —PO 2 (OC 1-3 alkyl) − , —PO 2 H(OC 1-3 alkyl), —PO(OC 1-3 alkyl) 2 , —CO 2 —, —CO 2 H, or —CO 2 (C 1-3 alkyl); and
X is N + or, if R 3 is absent, X is N;
wherein said inflammatory, autoimmune and/or allergic disorder is selected from: psoriasis, atopic dermatitis (atopic eczema), contact dermatitis, xerotic eczema, seborrheic dermatitis, neurodermitis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis (Duhring's Disease), autoeczematization, dermatomyositis, hyper-IgE (Buckley) syndrome, Wiskott-Aldrich syndrome, anaphylaxis, food allergy, allergic reactions to venomous stings, acute urticarias, chronic urticarias, physical urticarias including aquagenic urticaria, cholinergic urticaria, cold urticaria (chronic cold urticaria), delayed pressure urticaria, dermatographic urticaria, heat urticaria, solar urticaria, vibration urticaria, adrenergic urticaria, urticaria angioedema, inflammatory bowel disease, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, diversion colitis (diverticulitis), Behçet's syndrome, indeterminate colitis, celiac disease, irritable bowel syndrome, post-operative ileus, eosinophilic gastroenteropathy, gastritis, chronic allergic rhinitis, seasonal allergic rhinitis (hay-fever), allergic conjunctivitis, chemical conjunctivitis, neonatal conjunctivitis, Sjögren syndrome, open-angle glaucoma, dry eye disease, diabetic macular edema, chronic obstructive pulmonary disease (COPD), allergic asthma, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, lung fibrosis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, reactive arthritis, polymyalgia rheumatica, multiple sclerosis, Guillain-Barre syndrome, Hashimoto's thyroiditis, Grave's disease, temporal arteritis, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, alopecia areata, a graft-versus-host disease, a host-versus-graft disease, or a transplant rejection.
2. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from psoriasis, atopic dermatitis (atopic eczema), contact dermatitis, xerotic eczema, seborrheic dermatitis, neurodermitis, dyshidrosis, discoid eczema, venous eczema, dermatitis herpetiformis (Duhring's Disease), autoeczematization, dermatomyositis, hyper-IgE (Buckley) syndrome, Wiskott-Aldrich syndrome, anaphylaxis, food allergy, or allergic reactions to venomous stings.
3. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from acute urticarias, chronic urticarias, physical urticarias including aquagenic urticaria, cholinergic urticaria, cold urticaria (chronic cold urticaria), delayed pressure urticaria, dermatographic urticaria, heat urticaria, solar urticaria, vibration urticaria, adrenergic urticaria, or urticaria angioedema.
4. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from inflammatory bowel disease, Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, diversion colitis (diverticulitis), Behçet's syndrome, indeterminate colitis, celiac disease, irritable bowel syndrome, post-operative ileus, eosinophilic gastroenteropathy, or gastritis.
5. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from chronic allergic rhinitis, seasonal allergic rhinitis (hay-fever), allergic conjunctivitis, chemical conjunctivitis, neonatal conjunctivitis, Sjögren syndrome, open-angle glaucoma, dry eye disease, or diabetic macular edema.
6. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from chronic obstructive pulmonary disease (COPD), allergic asthma, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonitis, or lung fibrosis.
7. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, reactive arthritis, or polymyalgia rheumatica.
8. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from multiple sclerosis, Guillain-Barre syndrome, Hashimoto's thyroiditis, Grave's disease, temporal arteritis, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, or alopecia areata.
9. The method of claim 1 , wherein said inflammatory, autoimmune and/or allergic disorder is selected from a graft-versus-host disease, a host-versus-graft disease or a transplant rejection.
10. The method of claim 1 , wherein said compound of formula 1 is administered in a pharmaceutical composition.
11. The method of claim 6 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
12. The method of claim 6 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The method of claim 7 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
14. The method of claim 7 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
15. The method of claim 8 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
16. The method of claim 8 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
17. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
18. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.